Regenerative Medicine Market: Rising Government Investments in Regenerative Medicine Research – The Chicago Sentinel

Biologics Market growth is largely driven by the rising prevalence of chronic diseases and genetic disorders, growing government investments in regenerative medicine research, and the increasing number of regenerative medicine companies globally.

What the Market Looks Like?

Predicted to grow at a CAGR of 23.8% during the forecast period, the global Regenerative Medicine market is estimated to reach USD 38.7 Billion by the end of 2024. North America to grow at the highest rate during the forecast period. North America has both public and private banks that store a limited number of cells and tissues.

Rising government investments in regenerative medicine research

The need for newer, better therapies for diseases/conditions such as cancer, diabetes, dermal diseases, musculoskeletal diseases, burns, and CVD has resulted in an overall increase in the number of research activities as well as the availability of funding for regenerative medicine research. Currently, several government organizations are investing in research institutes to develop advanced technologies in cell therapy. For instance, in January 2016, the government of Canada granted USD 20 million to the Centre for Commercialization of Regenerative Medicine. This grant will be utilized for establishing a stem-cell therapy development facility in Toronto, Canada. In addition, the NIH funding for the development of cell therapies is increasing significantly, annually.

The US is the major participant in the global regenerative medicine research sector, with various organizations in the country supporting regenerative medicine research. Since 2004, the California Institute of Regenerative Medicine (CIRM) has sponsored over 750 projects, with over USD 2.98 billion in funding. The NIH also funded USD 4.8 billion for research and development under the 21st Century Cures Act, including funding for regenerative medicine, for a ten-year period starting in 2017. Furthermore, under the 21st Century Cures Act, the FDA launched novel procedures in 2017, such as the regenerative medicine advanced therapy (RMAT) designation, to accelerate the access to the most promising regenerative medicine therapies.

Owing to the importance of regenerative medicine, the number of government and private bodies supporting R&D activities related to stem cell therapeutics and regenerative medicine is expected to increase further in the coming years.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579

What Drives the Market?

The growth of the global market for Regenerative Medicine is primarily influenced by the following factors:

The other factors supporting market growth include the growing pipeline of regenerative medicine products and the rising demand for organ transplantation.

Geographical growth scenario of Regenerative Medicine Market

Geographically, the Regenerative Medicine market has been studied for North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest market share in 2018 and is also projected to witness the highest growth in the forecast period.

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=65442579

Leading market players and strategies adopted

The prominent players in the Regenerative Medicine market include Kite Pharma (US), Novartis (Switzerland), Vericel Corporation (US), Integra LifeSciences (US), Wright Medical (US), MiMedx (US), Osiris Therapeutics (US), Stryker Corporation (US), and Spark Therapeutics (US).

About MarketsandMarketsMarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the Growth Engagement Model GEM. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write Attack, avoid and defend strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead.

MarketsandMarketss flagship competitive intelligence and market research platform, Knowledge Store connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact Us:Mr. Shelly SinghMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL60062USA: +1-888-600-6441Email:sales@marketsandmarkets.comVisit Our Website: https://www.marketsandmarkets.com

Visit link:
Regenerative Medicine Market: Rising Government Investments in Regenerative Medicine Research - The Chicago Sentinel

Research Antibodies and Reagents Market Worth $14.56 Billion by 2025 – Exclusive Report by Meticulous Research – GlobeNewswire

London, Nov. 25, 2019 (GLOBE NEWSWIRE) -- According to a new market research report Research Antibodies and Reagents Market by Product (Reagent [Sample Preparation (Media, Probe, Buffer), Antibody Production Reagent], Antibody [Type, Source, Research Area]), Technology (Western Blot, ELISA), Application, End-User - Global Forecast to 2025, published by Meticulous Research, the research antibodies and reagents market is expected to grow at a CAGR of 6% from 2019 to 2025 to reach $14.56 billion by 2025.

Research antibodies act as a vital tool in laboratory techniques that are conducted for research purpose. Due to their high specificity and sensitivity, antibodies and associated reagents make an exquisite tool aiding in the detection of molecules and its analysis, which enables the researchers to draw conclusions related to drug target, disease occurrence, and immune system pathways. The rising proteomics and genomic research studies, increase in the funding for research activities, and growing industry-academia collaborations are the key factors driving steady growth in the global research antibodies and reagents market.

Request Sample Report:https://www.meticulousresearch.com/request-sample-report/cp_id=5055

In recent years, the funding for healthcare research projects has increased significantly. According to the Research America, investment in medical and health research and development by the U.S. has increased by 18.1% between 2014 and 2017. In 2017, total expenditure on medical and health R&D in the U.S. was $182.3 billion. Industry, including pharmaceutical, medical technology, biotechnology and health IT companies, accounted for the largest share of the U.S. investment in medical and health R&D over the reporting period. Similarly, in Europe, according to European Union (EU), Horizon 2020 program was launched in 2016, with an investment of $88.5 billion (80 billion); of which around 10% (~$9 billion) was utilized for healthcare sector. The initiative was aimed at developing and supporting personalized medicine projects. Also, during the period of 2014-2016, the European Commission invested more than $2.7 billion (2.4 billion) in projects that supported innovation in personalized medicine. Therefore, such increase in funding has led to rise in research activities in pharmaceutical and biotechnology industries, thereby boosting the demand for research antibodies and reagents.

The research antibodies and reagents market study presents historical market data in terms of value (2017 and 2018), estimated current data (2019), and forecasts for 2025 by product, technology, application, end user, and geography. The study also evaluates industry competitors and analyzes their market share at the global and regional levels.

Based on product, reagents segment is estimated to account for the largest share of the overall research antibodies and reagents market in 2019 and is slated to grow at the fastest CAGR during the forecast period. The large share of this segment is attributed to recurrent use of reagents in many research assays and techniques and increasing developments in research reagents.

Based on technology, western blotting segment is estimated to account for the largest share of the overall research antibodies and reagents market in 2019. This is mainly attributed to increasing focus on initiating developments in diagnosis and therapy procedures and rising research funding for biomarker discovery and antibody & cell-based products. On the other hand, Enzyme-linked Immunosorbent Assay (ELISA) is slated to grow at the fastest CAGR during the forecast period due to increasing use of ELISA technology for screening of active ingredients and validation of obtained hits in drug discovery.

Based on application, proteomics segment is estimated to hold the largest share of the overall research antibodies and reagents market in 2019. This is mainly attributed to the increase in search for ideal candidates for use as anti-cancer drugs, need for designing more effective drugs, assessment of drug efficacy and patient response, and development of antibodies especially monoclonal antibodies. Growing use of proteomic technologies in development of target-based therapies also supports the large share and growth in this market.

Based on end user, pharmaceutical and biotechnology companies segment is estimated to hold the largest share of the overall research antibodies and reagents market in 2019, due to high adoption of research antibodies & reagents in proteomics research and drug discovery and development programs. Rising focus of industry players on developing innovative therapeutics for chronic diseases is contributing to the growth of this market. On the other hand, the demand for research antibodies from contract research organizations (CROs) is slated to grow fastest during the forecast period, mainly due to increase in outsourcing activities by pharmaceutical industries to CROs.

The report also includes extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2016-2019). The research antibodies and reagents market has witnessed number of partnerships & agreements in the recent years. For instance, in January 2018, Abcam plc (U.K.) entered into an agreement with Roche to facilitate licensing of product portfolio of Spring Bioscience Corporation to Abcam for research use only (RUO) applications, which includes recombinant antibodies. Similarly, in October 2017, Bio-Techne Corporation (U.S.) entered into an agreement with Joint Consortia Framework for the development of research antibodies & antibody-based reagents. Similarly, in January 2018, Illumina, Inc. (U.S.) launched iSeq 100 sequencing system, which offers exceptional data accuracy, at a low capital cost.

The global research antibodies and reagents market is highly fragmented with the presence of key players, such as, Abcam plc (U.K.), Merck KGaA (Germany), Cell Signaling Technology, Inc. (U.S.),GE Healthcare (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann La-Roche Ltd (Switzerland), Rockland Immunochemicals Inc. (U.S.), Johnson & Johnson (U.S.), Agilent Technologies, Inc. (U.S.), Eli Lily and Company (U.S.), Becton Dickinson and Company (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), GenScript Biotech Corporation (U.S.), Lonza (Switzerland), Bio-Techne Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Santa Cruz Biotechnology, Inc. (U.S.), and BioLegend, Inc.(U.S.) among others.

Browse key industry insights spread across 280 pages with 256 market data tables & 61 figures & charts from the report:https://www.meticulousresearch.com/product/research-antibodies-reagents-market-5055/

Scope of the Report:

Research Antibodies and Reagents Market, by Product

Research Antibodies and Reagents Market, by Technology

Research Antibodies and Reagents Market, by Application

Research Antibodies and Reagents Market, by End User

Research Antibodies and Reagents Market, by Geography

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5055

Related Reports:Immunoassay Market by Product (Kits and Reagents, Analyzers, Software), Platform (Chemiluminescence, Radioimmunoassays) Application (Infectious Diseases, Cardiology), End-User (Hospitals, Academic Laboratories), and Geography - Global Forecast to 2025, read more:https://www.meticulousresearch.com/product/immunoassay-market-4982/

Cell Culture Market by Product [Consumables (Media, Reagents, Sera, FBS, Antibiotics, Growth Factor, Buffer), Equipment (Bioreactor, Centrifuge)], Application (Biopharmaceutical, Cancer, Stem Cell), and End User (Pharma, Research)- Global Forecast to 2024, read more:https://www.meticulousresearch.com/product/cell-culture-market/

About Meticulous Research

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to details.

Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, with the help of its unique research methodologies, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions.

With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Follow this link:
Research Antibodies and Reagents Market Worth $14.56 Billion by 2025 - Exclusive Report by Meticulous Research - GlobeNewswire

Visiongain Report Offers Transformative Insights on the $3.2bn Protein Expression Market – PRNewswire

LONDON, Nov. 25, 2019 /PRNewswire/ -- The global protein expression market is estimated at $1.8bn in 2018. Visiongain estimated that the prokaryotic expression system accounted for 40.0% of the global protein expression market.

How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 201-page report you will receive 70 tables and 115 figures all unavailable elsewhere.

The 201-page Visiongain report provides clear detailed insight into the global protein expression market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-protein-expression-market-forecast-to-2029/#download_sampe_div

Report Scope

Global Protein Expression Market forecaststo 2029

Global Protein Expression Market forecaststo 2029by Expression System: Cell-free Expression System Prokaryotic/ Bacterial Expression System Yeast Cell Expression Systems Algal-based Expression Systems Insect Cell Expression Systems Mammalian Cell Expression Systems

Global Protein Expression Market forecasts to 2029by Product & Services: Reagents Expression Vectors Competent Cells Instruments Services

Global Protein Expression Market forecasts to 2029by Application: Therapeutic Applications Industrial Application Research Application

Global Protein Expression Market forecaststo 2029by End-User: Pharmaceutical and Biotechnology Companies Academic Research Institutes Contract Research Organizations (CROs)

Global Protein Expression Market forecaststo 2029by National Market: North America: US, Canada EU: Germany, France, UK, Italy, Spain Asia: Japan, China, India

Assessment of selectedleading companies that hold major market shares in the protein expression industry: Agilent Technologies Bio-Rad Technologies EMD Milipore New England Biolabs, Inc. Oxford Expression Technologies, Ltd. Promega Corporation Qiagen NV Takara Bio, Inc. Thermo Fisher Scientific, Inc.

Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the protein expression market. Moreover, this report discussesfactors that drive and restrain the protein expression market.

Key Questions Answered by This Report: What is the current size of the protein expression market? How much will this market be worth from 2019-2029? What will be the main drivers and restraints for this market? What are the different segments of the protein expression market? How much will each of these segments be worth during 2019-2029 and how will their market shares change during this period? What are the largest national protein expression markets? How much will these markets be worth from 2019-2029? How will the emerging markets affect the market shares of the mature markets? What are the most prominent companies in the market? What products and services do they offer, and what are the main features and advantages of them? What are the main trends affecting the market? What technologies will increase in prominence between 2019 and 2029? What are the advantages of these technologies? What are the main strengths, weaknesses, opportunities and threats for the market? What are the social, technological, economic and political factors affecting the market?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-protein-expression-market-forecast-to-2029/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

Abgenex Agilent Technologies Inc.Anthem BiosciencesAstraZenecaBayerBio-Rad TechnologiesBiotechnology Industry Research Assistance Council BioTek InstrumentsBrammer BioBristol-Myers Squibb Cancer Research UK Centers for Disease Control and Prevention Clontech Laboratories, Inc. Department of Biotechnology EMD MilliporeGIMDx, Inc. HD Biosciences Co., Ltd.Icagen, Inc. IncellDx, IncInnoCore PharmaceuticalsInSphero AG Institute for Molecular Medicine Finland JanssenLabcyte Inc.LikardaLuxcel Biosciences LtdMerckMerck & Co., IncNew England Biolabs Inc.Novo Nordisk Foundation Center for Biosustainability On Target Co., Ltd. OriGeneOxford Expression Technologies LtdPharmaceutical Research and Manufacturers of America Promega CorporationQiagen NVSanofiSciGenomSigma-Aldrich CorporationSino BiologicalsTakara Bio Inc.Takeda Pharmaceutical Company Technical University of Denmark Thermo Fisher Scientific Inc.UCBWaferGen Bio-systems, Inc. World Health Organization

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Immunochemistry Reagents, Analyzers and Test Kits Market 2019-2029

Pharmaceutical Contract Manufacturing Market 2019-2029

Global Medical Device Contract Manufacturing Market Forecast 2019-2029

3D Printing for Healthcare Market Report 2019-2029

Global Stem Cell Technologies and Applications Market 2019-2029

SOURCE Visiongain

Go here to read the rest:
Visiongain Report Offers Transformative Insights on the $3.2bn Protein Expression Market - PRNewswire

Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions – Business Wire

PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (Immune-Onc), a privately held cancer immunotherapy company, announced today the addition of several industry veterans to its executive team and advisory boards and the promotion of An Song, Ph.D. to Chief Scientific Officer from Senior Vice President of Development Sciences. Dr. Paul Woodard joins Immune-Onc from Bellicum Pharmaceuticals, Inc. where he most recently served as Senior Vice President, Clinical and Medical Affairs.

We are thrilled to add such seasoned and strategic individuals to the executive and advisory teams guiding Immune-Onc through its next phase of growth as a clinical stage company, said Charlene Liao, Ph.D., Co-founder and Chief Executive Officer of Immune-Onc. As our Chief Medical Officer, Paul brings the right combination of deep expertise in oncology paired with proven strategic leadership and experience building teams and functions in a startup environment. The appointment of An to Chief Scientific Officer is a reflection of the contributions she has already made to the company in her current role and a recognition of the value that her experience will bring in guiding the translation of our science into development.

I cant imagine a more exciting time to join Immune-Onc, said Dr. Woodard. I was first drawn to the novel science underlying the portfolio. As I learned more about Immune-Onc and their authentic passion for improving patient lives, it became clear to me that this was a company that I wanted to contribute to in a meaningful way with the goal of bringing much needed new treatment options to people with hard-to-treat cancers like acute myeloid leukemia.

About Paul Woodard, M.D.

As Chief Medical Officer, Dr. Woodard will be responsible for clinical leadership and medical oversight of the Immune-Onc portfolio. These activities will include review and input of IND submissions, clinical protocol development and medical oversight of Immune-Onc trials, and oversight of internal and external clinical development, biometrics, safety, and regulatory functions and compliance.

Dr. Woodard has an extensive hematology and oncology background gained in academia and industry. His academic experience focused on pediatric hematopoietic stem cell transplantation and hematologic disorders at world-renowned institutions, including St. Jude Childrens Research Hospital, University of California, San Francisco, and Childrens Hospital, Los Angeles. In addition to patient care, at St. Jude, Dr. Woodard was responsible for Phase 1/2 trials in pediatric hematopoietic stem cell transplantation for malignant and non-malignant disorders.

Prior to joining Immune-Onc, Dr. Woodard worked on a wide range of drug development projects in solid tumors, hematologic malignancies, and non-malignant hematologic disorders. At Exelixis, Dr. Woodard worked on small molecule tyrosine kinase inhibitors for solid tumors. At Amgen, Dr. Woodard was the global development leader for Nplate (romiplostim) in immune thrombocytopenia and myelodysplastic syndromes. At Genentech, Dr. Woodard was the global development team leader for Tecentriq (atezolizumab) in hematologic malignancies and was an integral team member for the development of Tecentriq combinations in solid tumors (including triple negative breast cancer) and hematologic malignancies. At Bellicum, Dr. Woodard was the Senior Vice President of Clinical and Medical Affairs, with oversight of the companys cellular therapy portfolio and clinical trials in hematologic malignancies and solid tumors.

Dr. Woodard earned his medical degree at the University of North Carolina and completed his residency at the University of Virginia and fellowships in pediatric hematology-oncology at the University of North Carolina and in pediatric blood and marrow transplantation at the University of Minnesota.

About An Song, Ph.D.

Dr. Song joined Immune-Onc in July 2018 as Senior Vice President of Development Sciences. In the newly created role of Chief Scientific Officer, Dr. Song will have overall accountability for translational development of Immune-Oncs portfolio and strategic oversight of research and antibody engineering.

Dr. Song is a translational scientist with 22 years of experience across basic research and drug development in oncology, autoimmunity, metabolic, infectious, and neurodegenerative diseases. Dr. Song joins Immune-Onc from Genentech where, as a Senior Director in BioAnalytical Sciences, she led the Assay Development and Technology group for the companys large molecule portfolio globally and was a member of numerous scientific review bodies within the Genentech Research and Early Development (gRED) organization. During her 16-year tenure at Genentech, Dr. Song contributed to, and oversaw 40+ IND/CTA and BLA/MAA regulatory filings for products including Rituxan, Avastin, Herceptin, Lucentis, Kadcyla and Tecentriq. In addition, Dr. Song played a significant role in the development and approval of Ocrevus.

Dr. Song received her Ph.D. in Biochemistry & Molecular Biology from Indiana University and completed a postdoctoral fellowship in immunology, followed by a faculty position as Assistant Professor (Research) at Stanford University. As an active member of the American Association of Pharmaceutical Scientists (AAPS), Dr. Song has served as an executive member of the Biotech Section and chair of the Therapeutic Product Immunogenicity (TPI) Focus Group/Community.

BOARD APPOINTMENTS

In addition, Immune-Onc bolstered its cadre of advisors with the appointment of Zhengbin (Bing) Yao, Ph.D. to its Board of Directors and Gregory Cosma, Ph.D. to its Scientific Advisory Board. Both Bing and Greg bring significant experience in helping early-stage companies navigate the complexity of drug development, commented Dr. Liao. Bing and Gregs perspectives are invaluable in supporting Immune-Onc in our mission to deliver transformative therapies to cancer patients.

About Zhengbin (Bing) Yao, Ph.D.

Dr. Yao has more than 20 years of experience in the biopharmaceutical industry, with a proven track record of successfully leading the discovery and development of multiple biotherapeutics. Dr. Yao is currently Chairman of the Board and CEO of Viela Bio. Prior to this role, he was Senior Vice President, Head of Respiratory, Inflammation and Autoimmune iMED at MedImmune/AstraZeneca. During his tenure at MedImmune, he played key leadership roles in the development and approval of three novel biologics for autoimmune, respiratory, and immune-oncology indications. Previously, Dr. Yao also served as Senior Vice President, Head of Immuno-Oncology Franchise, AstraZeneca, as well as CEO for WuXi-MedImmune Joint Venture. Dr. Yao joined MedImmune in 2010 from Genentech, where he was the Head of Project Team Leaders for Immunology, Infectious Diseases, Neuroscience, and Metabolic Disease. He was Vice President and Head of Research for Tanox, before the company was acquired by Genentech in 2007. Dr. Yao also held several positions of increasing responsibility at Aventis and Amgen and currently serves on the Board of Directors for NexImmune. Dr. Yao received his Ph.D. in Microbiology and Immunology from the University of Iowa, followed by postdoctoral work at Immunex.

About Gregory Cosma, Ph.D.

As a former executive at Genentech and Bristol-Myers Squibb, Dr. Cosma has a long track record of success leading companies in translating science into approved therapies. As Vice President of Research and Early Development at Genentech from 2010-2019, Dr. Cosma led the Safety Assessment organization comprising Toxicology, Pathology, Product Quality and Occupational Toxicology and Nonclinical Operations. He also chaired the Genentech Development Review Committee (DRC), overseeing nonclinical development of the Genentech pipeline from Research to First-in-Human studies. While at Bristol-Myers Squibb from 2003-2010, Dr. Cosma held roles as the Executive Director for Drug Safety Evaluation and as the Therapeutic Area Head for Metabolic Diseases. Prior to these roles, Dr. Cosma was a Research Fellow at Pharmacia-Pfizer and an assistant professor in the College of Veterinary Medicine and Biomedical Sciences at Colorado State University. Dr. Cosma earned his doctorate in Pharmacology/Toxicology at the University of Kansas.

ABOUT IMMUNE-ONC THERAPEUTICS, INC.

Immune-Onc Therapeutics, Inc. (Immune-Onc) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline built upon strategic collaborations and cutting-edge research from The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Its lead program, an antibody targeting LILRB4, is being developed to treat acute myeloid leukemia and other cancers. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit http://www.immune-onc.com.

Follow this link:
Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions - Business Wire